Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 19/20 | 0.68 |
| ▸ | GSPT1 | P15170 | 8/20 | 0.68 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.68 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.68 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.55 |
| ▸ | CSNK1A1 | P48729 | 3/20 | 0.52 |
| ▸ | IKZF2 | Q9UKS7 | 1/20 | 0.46 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23239946 | 0.93 | CRBN (0.72) | CRBNGSPT1DDB1IKZF3CYP2C19 | |
| SCHEMBL23240227 | 0.90 | CRBN (0.63) | CRBNGSPT1DDB1IKZF3CYP2C19 | |
| SCHEMBL23240028 | 0.90 | CRBN (0.70) | CRBNGSPT1DDB1IKZF3CYP2C19 | |
| SCHEMBL23239939 | 0.88 | CRBN (0.75) | CRBNGSPT1DDB1IKZF3CYP2C19 | |
| SCHEMBL23239934 | 0.88 | CRBN (0.75) | CRBNGSPT1DDB1IKZF3CYP2C19 | |
| SCHEMBL23239944 | 0.88 | CRBN (0.67) | CRBNGSPT1DDB1IKZF3CYP2C19 | |
| SCHEMBL23240026 | 0.88 | CRBN (0.65) | CRBNGSPT1DDB1IKZF3CYP2C19 | |
| SCHEMBL23240228 | 0.88 | CRBN (0.70) | CRBNGSPT1DDB1IKZF3CYP2C19 | |
| SCHEMBL23240149 | 0.88 | CRBN (0.67) | CRBNGSPT1DDB1IKZF3CYP2C19 | |
| SCHEMBL23240154 | 0.88 | CRBN (0.65) | CRBNGSPT1DDB1IKZF3CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240216355-A1 | PHARMACEUTICAL COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF A DISEASE OR DISORDER CAUSED BY OR ASSOCIATED WITH ONE OR MORE PREMATURE TERMINATION CODONS | MONTE ROSA THERAPEUTICS AG (CH) | 2024-07-04 | — | — | US | disclosed |
| WO-2022256623-A1 | E3 LIGASE FUSION PROTEINS FOR PROXIMITY DETECTION | MONTE ROSA THERAPEUTICS, INC. (US) | 2022-12-08 | — | — | WO | disclosed |
| WO-2021069705-A1 | ISOINDOLINONE COMPOUNDS | MONTE ROSA THERAPEUTICS (CH) | 2021-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240216355-A1 | PHARMACEUTICAL COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF A DISEASE OR DISORDER CAUSED BY OR ASSOCIATED WITH ONE OR MORE PREMATURE TERMINATION CODONS | UPF1, NSUN2, RTF2 | CRBN 524/4885GSPT1 1795/4885DDB1 2502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.